

Table 3.4
Verified Outcomes (Annualized Percentages) by Age at Enrollment for SRC Super Cohort Participants¹
 Data as of: March 31, 2018; Events through September 30, 2010 and March 31, 2018

	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
Outcomes through Extension Study 2005-2010					
Number randomized	117634	14781	22638	53171	27044
Mean follow-up (months)	142.7	154.9	151.9	142.9	128.1
Cardiovascular²					
CHD ³	5434 (0.39%)	201 (0.11%)	489 (0.17%)	2362 (0.37%)	2382 (0.83%)
CHD death ⁴	1891 (0.14%)	49 (0.03%)	104 (0.04%)	693 (0.11%)	1045 (0.36%)
Clinical MI	4044 (0.29%)	159 (0.08%)	398 (0.14%)	1834 (0.29%)	1653 (0.57%)
Angina ⁵	3623 (0.38%)	139 (0.11%)	423 (0.22%)	1749 (0.41%)	1312 (0.63%)
CABG/PTCA	6113 (0.44%)	241 (0.13%)	711 (0.25%)	3161 (0.50%)	2000 (0.69%)
Carotid artery disease	1111 (0.08%)	48 (0.03%)	117 (0.04%)	520 (0.08%)	426 (0.15%)
Congestive heart failure, WHI ⁵	2797 (0.29%)	78 (0.06%)	201 (0.11%)	1096 (0.26%)	1422 (0.68%)
Stroke	4255 (0.30%)	124 (0.06%)	319 (0.11%)	1856 (0.29%)	1956 (0.68%)
PVD	984 (0.07%)	24 (0.01%)	88 (0.03%)	460 (0.07%)	412 (0.14%)
Coronary disease ⁶	11771 (0.84%)	455 (0.24%)	1244 (0.43%)	5456 (0.86%)	4616 (1.60%)
Total cardiovascular disease	16773 (1.20%)	626 (0.33%)	1662 (0.58%)	7667 (1.21%)	6818 (2.36%)
Fractures²					
Hip fracture	2955 (0.21%)	63 (0.03%)	186 (0.06%)	1108 (0.18%)	1598 (0.55%)
Outcomes through Extension Study 2010-2020					
Number randomized	117634	14781	22638	53171	27044
Mean follow-up (months)	188.2	213.9	209.0	189.8	153.8
Cancer					
Breast cancer	10211 (0.55%)	1330 (0.50%)	2155 (0.55%)	4753 (0.57%)	1973 (0.57%)
Invasive breast cancer	8516 (0.46%)	1059 (0.40%)	1785 (0.45%)	3982 (0.47%)	1690 (0.49%)
Non-invasive breast cancer	1833 (0.10%)	291 (0.11%)	398 (0.10%)	839 (0.10%)	305 (0.09%)
Ovarian cancer	971 (0.05%)	118 (0.04%)	184 (0.05%)	457 (0.05%)	212 (0.06%)
Endometrial cancer ⁷	1461 (0.13%)	161 (0.10%)	325 (0.13%)	678 (0.14%)	297 (0.15%)
Colorectal cancer	2308 (0.13%)	131 (0.05%)	295 (0.07%)	1141 (0.14%)	741 (0.21%)
Other cancer ⁸	12692 (0.69%)	1165 (0.44%)	2129 (0.54%)	6220 (0.74%)	3178 (0.92%)
Total cancer	25348 (1.37%)	2690 (1.02%)	4687 (1.19%)	12062 (1.43%)	5909 (1.70%)
Deaths					
Cardiovascular deaths	7951 (0.43%)	163 (0.06%)	456 (0.12%)	3134 (0.37%)	4198 (1.21%)
Cancer deaths	8557 (0.46%)	537 (0.20%)	1143 (0.29%)	4161 (0.49%)	2716 (0.78%)
Other known cause	8577 (0.46%)	253 (0.10%)	659 (0.17%)	3741 (0.44%)	3924 (1.13%)
Unknown cause	1738 (0.09%)	55 (0.02%)	164 (0.04%)	909 (0.11%)	610 (0.18%)
Total death	26823 (1.45%)	1008 (0.38%)	2422 (0.61%)	11945 (1.42%)	11448 (3.30%)
Death plus post-WHI deaths⁹	39989 (1.86%)	1348 (0.44%)	3241 (0.72%)	17182 (1.75%)	18218 (4.34%)

¹ The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

² Cardiovascular diseases and hip fracture are not adjudicated for SRC Super Cohort participants during the WHI Extension Study 2010-2020. Reported statistics represent experience during the original program and the Extension Study 2005-2010.

³ "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Study 2005-2010.

⁴ "CHD death" includes definite and possible CHD death.

⁵ Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010. Reported statistics represent experience during the original program.

⁶ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, and CABG/PTCA; Q-wave MI, angina, and congestive heart failure were not collected in the WHI Extension Study 2005-2010.

⁷ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

⁸ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

⁹ Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.